Preclinical studies revealed that ONC201 has robust anti-tumor effects by activating the TRAIL pathway through an upstream dual blockade of Akt and ERK that activates Foxo3a to transcriptionally up-regulate the TRAIL gene [4, 6, 7]. Here, AKT1 is linked to neoplasm.